DESIGN OF AN ENCAPSULATED TOPICAL FORMULATION FOR CHEMOPREVENTION OF SKIN CANCER

被引:5
|
作者
Ravikumar, Padmini [1 ,2 ]
Tatke, Pratima [2 ]
机构
[1] SVKMs Dr Bhanuben Nanavati Coll Pharm, VM Rd, Bombay 400056, Maharashtra, India
[2] CU Shah Coll Pharm, Bombay 400047, Maharashtra, India
来源
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH | 2019年 / 10卷 / 01期
关键词
Skin cancer; Microemulsion; Resveratrol; Antioxidant; Antitvrosinase; DELIVERY; ACID;
D O I
10.13040/IJPSR.0975-8232.10(1).309-19
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study aims to design resveratrol loaded microemulsion (ME) topical formulation for use in skin cancer. Encapsulation of resveratrol can improve its intrinsic solubility and enhance penetration into the skin for topical use as an alternative to injectablcs. Preformulation studies by DSC and FTIR confirmed the compatibility of chosen excipients with resveratrol. Resveratrol loaded microemulsion was developed using phase diagrams based on oleic acid. labrasol and transcutol P as the oil phase, surfactant and co-surfactant respectively. Optimization was based on the particle size and % drug diffused. Optimized resveratrol loaded microemulsion was transparent and stable without phase separation. Optimized ME had an average particle size of 243 nm, zeta potential -32.9 +/- 2.5 mV and % drug content of 92.216 +/- 1.056. Optimized resveratrol ME was incorporated into a gel base to form a microemulgel that exhibited a spreadability of 34.3 +/- 0.34 gcm/s, the viscosity of 6000 +/- 1.67 cps and sustained in-vitro and ex-vivo drug release. Amount of drug diffused (in-vitro) at the end of 24 h was 98.21 +/- 0.03% from the conventional gel. In comparison, 71.11 +/- 0.47 and 68.15 +/- 0.12 was the % drug diffused from the ME gel. Results of drug retention for both in-vitro as well as ex-vivo permeation study was considerably higher for resveratrol microemulgel than control. Data of antioxidant activity, tyrosinase inhibition. and cytotoxicity in B16F10 melanoma cell line prove that resveratrol loaded ME gel is a promising treatment option for skin cancer chemoprevention.
引用
收藏
页码:309 / 319
页数:11
相关论文
共 50 条
  • [41] Nicotinamide for Skin-Cancer Chemoprevention in Transplantation
    Schmults, Chrysalyne D.
    Jambusaria-Pahlajani, Anokhi
    Ruiz, Emily
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (26): : 2493 - 2493
  • [42] CHEMOPREVENTION AND TREATMENT OF SKIN-CANCER WITH RETINOIDS
    PECK, GL
    CANCER SURVEYS, 1983, 2 (02) : 315 - 326
  • [43] Oral nicotinamide: The role in skin cancer chemoprevention
    Giacalone, Serena
    Spigariolo, Cristina B.
    Bortoluzzi, Paolo
    Nazzaro, Gianluca
    DERMATOLOGIC THERAPY, 2021, 34 (03)
  • [44] Nicotinamide for skin cancer chemoprevention in transplant recipients
    Allen, Nicholas
    Martin, Andrew
    Damian, Diona
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 89 - 89
  • [45] Nicotinamide for Skin-Cancer Chemoprevention REPLY
    Chen, Andrew C.
    Martin, Andrew J.
    Damian, Diona L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (08): : 790 - 790
  • [46] Skin-Cancer Chemoprevention in Transplant Recipients
    Miller, David M.
    Emerick, Kevin S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (09): : 844 - 844
  • [47] Skin penetration and formulation design
    Hadgraft, Jonathan
    Lane, Majella E.
    INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, 2012, 34 (04) : 370 - 370
  • [48] Topical treatments for skin cancer
    Cullen, Jason K.
    Simmons, Jacinta L.
    Parsons, Peter G.
    Boyle, Glen M.
    ADVANCED DRUG DELIVERY REVIEWS, 2020, 153 (153) : 54 - 64
  • [49] Topical pharmacotherapy for skin cancer
    Micali, Giuseppe
    Lacarrubba, Francesco
    Nasca, Maria Rita
    Schwartz, Robert A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (06) : 979.e1 - 979.e12
  • [50] Topical agents for oral cancer chemoprevention: A systematic review of the literature
    Chau, Lucy
    Jabara, Justin T.
    Lai, Wanda
    Svider, Peter F.
    Warner, Blake M.
    Lin, Ho-Sheng
    Raza, S. Naweed
    Fribley, Andrew M.
    ORAL ONCOLOGY, 2017, 67 : 153 - 159